- Home
- STTK vs TLSI Comparison
STTK vs TLSI Comparison
Compare STTK & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- TLSI
- Stock Information
- Founded
- STTK 2016
- TLSI 2010
- Country
- STTK United States
- TLSI United States
- Employees
- STTK N/A
- TLSI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- STTK Health Care
- TLSI Health Care
- Exchange
- STTK Nasdaq
- TLSI Nasdaq
- Market Cap
- STTK 37.6M
- TLSI 204.0M
- IPO Year
- STTK 2020
- TLSI N/A
- Fundamental
- Price
- STTK $0.83
- TLSI $5.04
- Analyst Decision
- STTK Hold
- TLSI Strong Buy
- Analyst Count
- STTK 4
- TLSI 5
- Target Price
- STTK $3.00
- TLSI $10.90
- AVG Volume (30 Days)
- STTK 410.6K
- TLSI 155.6K
- Earning Date
- STTK 07-31-2025
- TLSI 08-13-2025
- Dividend Yield
- STTK N/A
- TLSI N/A
- EPS Growth
- STTK N/A
- TLSI N/A
- EPS
- STTK N/A
- TLSI N/A
- Revenue
- STTK $4,606,000.00
- TLSI $32,141,000.00
- Revenue This Year
- STTK N/A
- TLSI $55.52
- Revenue Next Year
- STTK N/A
- TLSI $54.76
- P/E Ratio
- STTK N/A
- TLSI N/A
- Revenue Growth
- STTK 69.65
- TLSI 46.20
- 52 Week Low
- STTK $0.69
- TLSI $3.50
- 52 Week High
- STTK $4.99
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- STTK 41.39
- TLSI 45.84
- Support Level
- STTK $0.77
- TLSI $4.78
- Resistance Level
- STTK $0.87
- TLSI $5.20
- Average True Range (ATR)
- STTK 0.08
- TLSI 0.31
- MACD
- STTK -0.02
- TLSI -0.03
- Stochastic Oscillator
- STTK 17.65
- TLSI 30.29
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.